ABSTRACT
Analysis of the experience gained during the last pandemic of 'swine' influenza A (H1N1) sw1 is presented with reference to clinical studies and etiotropic therapy. The mechanism of development of severe pneumonia as a result of mutations at the binding site of hemagglutinin receptor enhancing a2'-3'-sialoside specificity and pneumotropism of the virus is described. The data on the efficiency of Ingavirin, a new Russian antiviral for the treatment of influenza, are reported.
Subject(s)
Influenza A Virus, H1N1 Subtype , Influenza, Human/drug therapy , Influenza, Human/physiopathology , Oseltamivir , Pneumonia, Viral/drug therapy , Viral Tropism/genetics , Zanamivir , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Communicable Diseases, Emerging/virology , Drug Resistance, Viral , Early Diagnosis , Hemagglutination, Viral/genetics , Humans , Influenza A Virus, H1N1 Subtype/drug effects , Influenza A Virus, H1N1 Subtype/pathogenicity , Influenza A Virus, H1N1 Subtype/physiology , Influenza Vaccines/therapeutic use , Influenza, Human/epidemiology , Influenza, Human/virology , Oseltamivir/administration & dosage , Oseltamivir/adverse effects , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/physiopathology , Pneumonia, Viral/virology , Prognosis , Severity of Illness Index , Viral Interference , Zanamivir/administration & dosage , Zanamivir/adverse effectsABSTRACT
Intermediatory relationships between the cholinergic and dopaminergic neurotransmission systems were analyzed using published data and the original experimental results obtained on Daphnia magna Straus, a new test object. Based on these results, the antihaloperidol activity of a series of M- cholinoblocking agents with different receptor selectivities were studied in comparison to the new cholinoblocker pentifin exceeding in the activity the classical antiparkinsonian drugs such as cyclodol, amedin, and norakin.
